RxDoctor Payments Data

German Crisol, MD

Family Medicine · Riverside, CANPI 1952333650

Payments from drug & device makers

$6,054in general payments, 2019–2025

Across 323 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$613
  • Novo Nordisk$576
  • Bayer$485
  • Johnson & Johnson$402
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,048100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,054 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$44,364
Medicare patients
66
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate118$137,866
JardianceEmpagliflozin68$93,430
XareltoRivaroxaban72$91,285
OzempicSemaglutide53$85,558
FarxigaDapagliflozin Propanediol49$59,367
TrulicityDulaglutide47$52,547
ProliaDenosumab32$50,257
EliquisApixaban47$47,594
MyrbetriqMirabegron28$35,676
VascepaIcosapent Ethyl31$20,598
TradjentaLinagliptin17$17,441
MounjaroTirzepatide13$12,690
EntrestoSacubitril/Valsartan11$11,654
Icosapent Ethyl20$10,780
Atorvastatin Calcium566$7,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Steglatro$388$143,765133 claims
Boehringer IngelheimJardiance, Tradjenta$287$110,87285 claims
Johnson & JohnsonXarelto$402$91,28572 claims
Novo NordiskOzempic$576$85,55853 claims
Lilly USA, LLCTrulicity, Mounjaro$126$65,23860 claims
AstraZenecaFarxiga$1,034$59,36749 claims
AmgenProlia$1,348$50,25732 claims
PfizerEliquis$43$47,59447 claims
Astellas Pharma US IncMyrbetriq$113$35,67628 claims
NovartisEntresto$178$11,65411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →